Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 2086-2096, 2007. First published October 22, 2007; 10.1373/clinchem.2007.095679
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.095679v1
53/12/2086    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, A. H.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, A. H.B.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow National Academy of Clinical Biochemistry
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:2086-2096.)
© 2007 American Association for Clinical Chemistry, Inc.

Evidence-Based Laboratory Medicine and Test Utilization

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure

NACB WRITING GROUP MEMBERS, Alan H.B. Wu1, Allan S. Jaffe2, Fred S. Apple3, Robert L. Jesse4, Gary L. Francis5, David A. Morrow6, L. Kristin Newby7, Jan Ravkilde8, W.H. Wilson Tang5, Robert H. Christenson9,a NACB COMMITTEE MEMBERS, Robert H. Christenson, Chair, Fred S. Apple, Christopher P. Cannon6, Gary L. Francis, Robert L. Jesse, David A. Morrow, L. Kristin Newby, Jan Ravkilde, Alan B. Storrow, W.H. Wilson Tang, Alan H.B. Wu, Section Leader

1 University of California at San Francisco, San Francisco, CA.
2 Mayo Clinic, Rochester, MN.
3 Hennepin County Medical Center, Minneapolis, MN.
4 Medical College of Virginia, Richmond, VA.
5 Cleveland Clinic, Cleveland, OH.
6 Harvard University, Boston, MA.
7 Duke University Medical Center, Durham, NC.
8 Aarhus University Hospital (Aalborg), Aalborg, Denmark.
9 University of Maryland School of Medicine, Baltimore, MD.

aAddress correspondence to this author at: University of Maryland School of Medicine, Laboratories of Pathology, University of Maryland Medical Center, 22 South Greene St., Baltimore, MD 21201. Fax 410-328-5880; e-mail rchristenson{at}umm.edu.




The following articles in journals at HighWire Press have cited this article:


Home page
 Circ Cardiovasc InterventHome page
A. Prasad, C. S. Rihal, R. J. Lennon, M. Singh, A. S. Jaffe, and D. R. Holmes Jr
Significance of Periprocedural Myonecrosis on Outcomes After Percutaneous Coronary Intervention: An Analysis of Preintervention and Postintervention Troponin T Levels in 5487 Patients
Circ Cardiovasc Intervent, August 1, 2008; 1(1): 10 - 19.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.